Trials
3 active
3 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Pulmonary Hypertension Associated With HFpEF (2 trials), Pulmonary Hypertension
- Main trialPhase 3
- “This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).”In the company’s words, NCT05983250 on ClinicalTrials.gov
Other drugs for Pulmonary Hypertension Associated With HFpEF
- Balcinrenone/dapagliflozinAstraZeneca · Phase 3
- DapagliflozinAstraZeneca · Phase 3
- HiCM-188HELP Therapeutics Co., Ltd. · Phase 3
- Omecamtiv mecarbilCytokinetics · Phase 3
- InclisiranNovartis · Phase 3
- EmpagliflozinBoehringer Ingelheim · Phase 3
Coming up2
- 30 Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- Mar 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 30 Jun 2026 | LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF | |
| Phase 3Active, not recruiting | 30 Jun 2028 | LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 | |
| Phase 3Enrolling by invitation | Mar 2029 | Long-Term Open-Label Extension Study of Oral Levosimendan |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026